Circulating EV Long RNA Profiles in SCLC

Overview

To identify the circulating extracellular vesicle long RNA (exLR) profiles in small cell lung cancer (SCLC) and explore the potential of exLR as biomarkers to predict the therapeutic effect of SCLC.

Eligibility

Inclusion Criteria:

1. Patients volunteered to participate in the study and have signed the informed consent.
2. Histological or cytological diagnosis of small cell lung cancer, and no indication of radical surgery or radiotherapy.
3. There are measurable lesions defined by RECIST standard v1.1. A lesion can be considered measurable only if the previously irradiated lesion has clear progression after radiotherapy and the previous irradiated lesion is not the sole lesion.
4. Initially treated patients who have not received any systematic therapy before. If have received postoperative adjuvant chemotherapy, the time to relapse is at least 6 months from the last adjuvant chemotherapy.
5. 18~75 years old; ECOG PS score: 0~1 points; expected survival time is more than 3 months.
6. The main organs's function meets the following criteria within 14 days before

   treatment

        （1）Routine blood test (without blood transfusion within 14 days): a) Hemoglobin (HB) ≥ 90 g
        / L; b) Absolute neutrophil (ANC) ≥ 1.5 × 109 / L; c) Platelets (PLT) ≥ 80×109/L
        （2）Biochemical examination: a) Total bilirubin (TBIL) ≤ 1.5 times of the upper limit of the
        normal (ULN); b) Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤
        2.5ULN.To patients with liver metastasis, ALT and AST ≤ 5ULN; c) Serum creatinine (Cr) ≤
        1.5ULN or creatinine clearance (CCr) ≥ 60ml / min; （3）Doppler ultrasound assessment: left
        ventricular ejection fraction (LVEF) ≥ the lower limit of the normal (50%).
        7. Patients with previously treated asymptomatic CNS metastases are allowed to participate
        in this study if all of the following criteria are met: a) No need for continuous
        corticosteroid therapy for CNS disease; b) No radiotherapy within 14 days prior to
        enrollment treatment; c) Imaging examination from the end of radiotherapy to screening
        period shows no CNS progression.
        8. Women of childbearing age should agree to conduct contraception (such as intrauterine
        devices, contraceptives or condoms) during the study and within 6 months after the end of
        the study; and the serum or urine pregnancy test is negative within 7 days prior to study
        enrollment and they must be non-lactating patients; Men should agree to conduct
        contraception during the study and within 6 months after the end of the study.
        Exclusion Criteria:
          1. Histological or cytological diagnosis of small cell and non-small cell mixed lung
             cancer.
          2. Patients who have previously received systemic chemotherapy, signal transduction
             inhibitors, targeted therapies, hormone and endocrine therapy.
          3. Patients with other malignant tumors occurred within 5 years prior to the enrollment,
             except those with cured cervical carcinoma in situ and superficial bladder tumors [Ta
             (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement
             membrane)] , basal or squamous cell skin cancer, and localized prostate cancer and
             ductal breast carcinoma in situ treated with radical surgery.
          4. Unresolved toxicity due to any previous treatment above CTC AE (4.0) level 2 or
             higher, excluding hair loss.
          5. Patients with symptomatic CNS metastases.
          6. Patients with uncontrolled pleural, pericardial, or peritoneal effusion requiring
             repeated drainage.
          7. Patients with any severe and/or uncontrolled disease, including:
               1. Patients with unsatisfactory blood pressure control (systolic blood pressure >150
                  mmHg, diastolic blood pressure >90 mmHg).
               2. Patients with myocardial ischemia or myocardial infarction of Grade I of higher
                  level, arrhythmia (including QTC ≥ 440ms) and congestive heart failure above
                  Grade 2 (New York Heart Association (NYHA) classification).
               3. Patients with active or uncontrolled severe infection (≥ CTC AE Level 2).
               4. Patients with a history of immunodeficiency, including HIV-positive or other
                  acquired, congenital immunodeficiency disease, or a history of organ
                  transplantation.
               5. Patients with poor control of diabetes (fasting blood glucose (FBG)>10mmol/L).
               6. Patients with urine protein ≥ ++ indicated by routine urine test, and confirmed
                  24-hour urine protein quantitation > 1.0 g.
               7. Patients with seizures requiring treatment.
          8. Patients undergone venous thrombosis events currently or within 6 months, such as
             cerebrovascular accidents (including transient ischemic attacks), deep vein
             thrombosis, and pulmonary embolism.
          9. Patients with a history of psychotropic drug abuse from which they are unable to
             abstain or with mental disorders.
         10. Patients who have participated in other clinical trials of anti-tumor drugs within
             four weeks.
         11. Patients with severe disease that threaten the safety of themselves or affect the
             completion of the study according to the investigators' judgment.